WallStSmart

Medtronic PLC (MDT)vsRxsight Inc (RXST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 26286% more annual revenue ($35.48B vs $134.48M). MDT leads profitability with a 13.0% profit margin vs -29.0%. MDT earns a higher WallStSmart Score of 56/100 (C).

MDT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.5Value: 7.3Quality: 5.0

RXST

Avoid

34

out of 100

Grade: F

Growth: 5.3Profit: 2.0Value: 5.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MDTSignificantly Overvalued (-255.7%)

Margin of Safety

-255.7%

Fair Value

$24.34

Current Price

$87.89

$63.55 premium

UndervaluedFair: $24.34Overvalued

Intrinsic value data unavailable for RXST.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$110.62B9/10

Large-cap with strong market position

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.0%8/10

Strong operational efficiency at 20.0%

Free Cash FlowQuality
$2.30B8/10

Generating 2.3B in free cash flow

RXST1 strengths · Avg: 10.0/10
Price/BookValuation
0.9x10/10

Reasonable price relative to book value

Areas to Watch

MDT1 concerns · Avg: 2.0/10
EPS GrowthGrowth
-11.8%2/10

Earnings declined 11.8%

RXST4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$263.69M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-14.0%2/10

ROE of -14.0% — below average capital efficiency

Revenue GrowthGrowth
-18.9%2/10

Revenue declined 18.9%

Comparative Analysis Report

WallStSmart Research

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin.

Bull Case : RXST

The strongest argument for RXST centers on Price/Book.

Bear Case : MDT

The primary concerns for MDT are EPS Growth.

Bear Case : RXST

The primary concerns for RXST are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

MDT profiles as a value stock while RXST is a turnaround play — different risk/reward profiles.

RXST carries more volatility with a beta of 1.15 — expect wider price swings.

MDT is growing revenue faster at 8.7% — sustainability is the question.

MDT generates stronger free cash flow (2.3B), providing more financial flexibility.

Bottom Line

MDT scores higher overall (56/100 vs 34/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Rxsight Inc

HEALTHCARE · MEDICAL DEVICES · USA

Rxsight Inc. is a pioneering healthcare technology company specializing in advanced vision correction solutions through its innovative diagnostic and surgical techniques in refractive eye surgery. Utilizing proprietary software and precision-guided laser technology, the company significantly improves patient outcomes and overall quality of life. Rxsight's strong intellectual property portfolio and strategic partnerships further enhance its competitive positioning within the expanding ophthalmic market. With a robust commitment to innovation and excellence, Rxsight is strategically poised for significant growth and impact in the evolving landscape of eye care.

Want to dig deeper into these stocks?